Lanreotide ( DrugBank: Lanreotide )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 6 |
| 73 | TSH-secreting pituitary adenoma | 1 |
| 85 | Idiopathic interstitial pneumonia | 1 |
| 298 | Hereditary pancreatitis | 1 |
67. Polycystic kidney disease
Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02127437 (ClinicalTrials.gov) | September 19, 2014 | 2/4/2014 | Lanreotide In Polycystic Kidney Disease Study | Lanreotide In Polycystic Kidney Disease Study | Autosomal Dominant Polycystic Kidney Disease (ADPKD | Drug: Lanreotide;Drug: saline | Assistance Publique - Hôpitaux de Paris | IPSEN pharmaceutical company, Boulogne-Billancourt, France | Completed | 18 Years | N/A | All | 159 | Phase 3 | France |
| 2 | NCT01616927 (ClinicalTrials.gov) | June 2012 | 6/6/2012 | Study of Lanreotide to Treat Polycystic Kidney Disease | The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: Lanreotide | University Medical Center Groningen | Leiden University Medical Center;Erasmus Medical Center;Radboud University | Active, not recruiting | 18 Years | 60 Years | All | 300 | Phase 3 | Netherlands |
| 3 | EUCTR2011-005017-37-NL (EUCTR) | 30/05/2012 | 21/05/2012 | To investigate the effect of Lanreotide on renal function decline in ADPKD patients | A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study | First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume. MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Somatuline Autogel Product Name: Lanreotide Product Code: BIM 23014 INN or Proposed INN: Lanreotide Other descriptive name: LANREOTIDE ACETATE | DIPAK Consortium | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 4 | NCT01354405 (ClinicalTrials.gov) | May 2011 | 13/5/2011 | Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) | The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease | Polycystic Liver Disease | Drug: Lanreotide | Radboud University | Ipsen | Completed | 18 Years | 70 Years | Both | 43 | N/A | Netherlands |
| 5 | NCT00771888 (ClinicalTrials.gov) | April 2008 | 13/10/2008 | Open-Label Extension of LOCKCYST Trial | Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers | Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney;Autosomal Dominant | Drug: lanreotide | Radboud University | Ipsen | Active, not recruiting | 18 Years | 88 Years | Both | 54 | Phase 2/Phase 3 | Belgium;Netherlands |
| 6 | NCT00565097 (ClinicalTrials.gov) | October 2007 | 28/11/2007 | Lanreotide as Treatment of Polycystic Livers | Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers | Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney, Autosomal Dominant | Drug: Placebo;Drug: Lanreotide | Radboud University | Ipsen | Completed | 18 Years | 88 Years | Both | 38 | Phase 2/Phase 3 | Belgium;Netherlands |
73. TSH-secreting pituitary adenoma
Clinical trial : 1 / Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-173772 | 22/1/2018 | 15/11/2017 | Phase 3 Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma | Phase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma | TSH-secreting pituitary adenoma | Intervention name : Lanreotide Acetate INN of the intervention : Lanreotide Dosage And administration of the intervention : Deep subcutaneous administration of 60 mg, 90 mg or 120 mg of lanreotide once every 4 weeks. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Teijin Pharma Limited | NULL | complete | 20 | BOTH | 8 | Phase 3 | Japan |
85. Idiopathic interstitial pneumonia
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-003687-78-IT (EUCTR) | 21/02/2012 | 05/03/2012 | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01 | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | INN or Proposed INN: LANREOTIDE ACETATE Product Name: Gallium68-Dota-Noc Product Code: NA INN or Proposed INN: NA Other descriptive name: NA | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy |
298. Hereditary pancreatitis
Clinical trials : 95 / Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-016082-29-BE (EUCTR) | 10/03/2010 | 25/11/2009 | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP | Paraduodenal pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis | Trade Name: Somatuline Autogel 90 mg Other descriptive name: LANREOTIDE ACETATE | Erasme hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Belgium |